Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors



Status:Completed
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2017
Start Date:November 2013

Use our guide to learn which trials are right for you!

A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer

The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to
assess the anti-tumor activity of MEK162 in combination with panitumumab.


Inclusion Criteria:

- Age ≥ 18 years

- Metastatic colorectal cancer

- Progression on or following standard therapy, or no standard therapy (phase Ib).
Progression on or following at least 2-prior fluoropyrimidine-containing chemotherapy
regimens (phase II)

- Written documentation of mutant or wild-type RAS

- Life expectancy ≥ 3 months

- ECOG performance status ≤ 2

Exclusion Criteria:

Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other
EGFR inhibitors

- Previous treatment with MEK-inhibitors

- History of severe infusion reactions to monoclonal antibodies.

- Symptomatic or untreated leptomeningeal disease

- Symptomatic brain metastasis

- Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as
assessed by ophthalmologic examination at baseline that would be considered a risk
factor for CSR/RVO and history of keratitis.

- Acute or chronic pancreatitis

- Clinically significant cardiac disease

- Not adequate hematologic, renal and hepatic function
We found this trial at
3
sites
?
mi
from
Leuven,
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
NY, NY
Click here to add this to my saved trials